Atlas
Back to Pharma Services
Target·Pharma Services

EUSA Pharma

Hemel Hempstead, UKeusapharma.com1expert edge

UK-based pharmaceutical company focused on rare disease and oncology, known for Sylvant (siltuximab) approved for idiopathic multicentric Castleman's disease; acquired J&J's Sylvant rights for $115M in 2019.

Why interesting to a deal team

Expert advised on $115M rare disease asset acquisition; shows deal experience with specialty pharma assets and global regulatory landscape.

Experts connected to this company

AM

Adam M. Wexner

Partner

Kirkland & Ellis LLP

LawyerChicago

He's Kirkland's go-to deal lawyer for pharma-services and CDMO transactions, sitting inside EW Healthcare's and Curewell Capital's live deal pipeline.

Sources